Full-Time

Regulatory Affairs CMC Director

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$196k - $240k/yr

Waltham, MA, USA

In Person

Category
Legal & Compliance (1)
Required Skills
FDA Regulations

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences or a related scientific discipline required; advanced degree preferred
  • 10+ years of experience in the biotech or pharmaceutical industry, with a minimum of 7 years in Regulatory Affairs, including significant CMC regulatory experience in clinical-stage and/or commercial biotechnology companies
  • Demonstrated experience leading CMC sections of biologics marketing applications (BLA/MAA) strongly preferred
  • Experience in rare disease drug development preferred
  • Strong working knowledge of FDA regulations, ICH guidelines, and global CMC regulatory requirements
  • Experience with EU and international regulatory frameworks related to clinical and commercial development is a plus
  • Deep understanding of the drug development process, accelerated regulatory pathways, and evolving global regulatory policy trends
  • Extensive experience with CTD structure, content, and global submission requirements
  • Proven ability to independently manage multiple complex programs in a fast-paced, dynamic environment
  • Strong strategic thinking skills with the ability to balance scientific, regulatory, and business considerations
  • Exceptional written and verbal communication skills, including regulatory writing and executive-level communication
  • Demonstrated ability to influence cross-functional stakeholders and senior leaders without direct authority
  • Highly collaborative leader and team player with a strong cross-functional mindset
  • Meticulous attention to detail with a commitment to quality and compliance
  • Positive, proactive, and resilient leader who embodies Dyne’s Core Values
  • Ability to drive timelines, meet firm deadlines, and adapt quickly to changing requirements and priorities
  • Embrace Dyne’s core values and culture
  • Role requires Onsite in Massachusetts - Waltham
Responsibilities
  • Lead and execute global CMC regulatory strategies for assigned programs across all phases of development, including IND, IMPD, BLA/MAA, and post-approval lifecycle management
  • Serve as the CMC regulatory strategist and program leader, proactively identifying regulatory risks, opportunities, and mitigation strategies in alignment with development and commercialization objectives
  • Provide strategic regulatory guidance to Manufacturing and Quality organizations to ensure global compliance and readiness for clinical and commercial supply
  • Oversee the planning, development, and delivery of high-quality CMC sections for global regulatory submissions and responses to Health Authority questions, including clinical and commercial manufacturing changes
  • Ensure alignment of CMC regulatory content with evolving regulatory expectations, guidance, and policy trends across regions
  • Coordinate and manage global regulatory submissions, maintenance of product registrations, and change control activities throughout the product lifecycle
  • Act as the primary CMC Regulatory Affairs point of contact for cross-functional teams, providing clear direction on global regulatory requirements, timelines, and risks
  • Represent Regulatory CMC in program, functional, and governance meetings, influencing decision-making without direct authority
  • Partner closely with Manufacturing, Quality, Clinical Operations, and Program Management to deliver critical regulatory milestones
  • Drive execution of regulatory policies, processes, and best practices to ensure consistent, compliant, and efficient regulatory operations
  • Leverage deep technical and regulatory expertise to anticipate challenges and enable proactive problem-solving
  • Mentor and support the development of regulatory team members, fostering a culture of collaboration, accountability, and continuous learning
  • Contribute to the advancement of Dyne’s regulatory capabilities by sharing knowledge, lessons learned, and regulatory insights across the organization
Desired Qualifications
  • Advanced degree in life sciences or a related field preferred
  • Demonstrated experience leading CMC sections of biologics marketing applications (BLA/MAA) strongly preferred
  • Experience in rare disease drug development preferred
  • Experience with EU and international regulatory frameworks related to clinical and commercial development is a plus
  • Onsite in Waltham, MA preferred

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
  • ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
  • Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]

What critics are saying

  • Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
  • FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
  • Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution

What makes Dyne Therapeutics unique

  • Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
  • Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
  • Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

-2%
Dyne Therapeutics
Dec 10th, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock | Dyne Therapeutics, Inc.

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.